FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100032900> ?p ?o ?g. }

• W2100032900 endingPage "1320" @default.
• W2100032900 startingPage "1295" @default.
• W2100032900 abstract "A systematic review was performed to compare the effectiveness and tolerability of lipid-based amphotericin B (AmB) formulations and conventional AmB in the treatment of systemic fungal infections.The literature and unpublished studies were searched using MEDLINE, EMBASE, Biological Abstracts, AIDSLINE, CANCERLIT, CRD database, Cochrane Controlled Trials Register, and other databases. Search terms included: amphotericin, liposom*, lipid*, colloid*, antifungal agents, and mycoses. Studies were selected according to predetermined criteria. The outcome measures reviewed were efficacy, mortality, renal toxicity, and infusion-related reactions. Meta-analyses and number-needed-to-treat (NNT) analyses were performed.Seven studies (8 publications) met the entry criteria. Meta-analysis showed that lipid-based formulations significantly reduced all-cause mortality risk by an estimated 28% compared with conventional AmB (odds ratio [OR], 0.72; 95% CI, 0.54 to 0.97). There was no significant difference in efficacy between the lipid-based formulations and conventional AmB (OR, 1.21; 95% CI, 0.98 to 1.49). AmB lipid complex (ABLC) and liposomal AmB (L-AmB) significantly reduced the risk of doubling serum creatinine by an estimated 58% (OR, 0.42; 95% CI, 0.33 to 0.54). There was no significant reduction in risk of infusion-related reactions with lipid-based formulations, although this was difficult to interpret given the lack of consistent control of confounding factors. Comparing the lipid-based formulations with conventional AmB, the overall NNT to prevent 1 death was 31. The NNT to prevent a doubling of serum creatinine for both ABLC and L-AmB compared with conventional AmB was 6.This study demonstrates advantages with lipid-based formulations over conventional AmB in terms of reduced risk of mortality and renal toxicity. Future trials in patients with proven fungal infection should control for factors such as premedication, infusion rates, fluid preloading, sodium/potassium supplementation, and concomitant medication." @default.
• W2100032900 created "2016-06-24" @default.
• W2100032900 creator A5005031753 @default.
• W2100032900 creator A5006549736 @default.
• W2100032900 creator A5006700282 @default.
• W2100032900 creator A5017044459 @default.
• W2100032900 creator A5026816951 @default.
• W2100032900 creator A5041768647 @default.
• W2100032900 creator A5043753326 @default.
• W2100032900 creator A5049454568 @default.
• W2100032900 creator A5057230537 @default.
• W2100032900 creator A5058024552 @default.
• W2100032900 creator A5062472038 @default.
• W2100032900 creator A5086478412 @default.
• W2100032900 creator A5090864045 @default.
• W2100032900 date "2003-05-01" @default.
• W2100032900 modified "2023-10-14" @default.
• W2100032900 title "A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations" @default.
• W2100032900 cites W1967229297 @default.
• W2100032900 cites W1970657632 @default.
• W2100032900 cites W1978263354 @default.
• W2100032900 cites W1986330094 @default.
• W2100032900 cites W1997338092 @default.
• W2100032900 cites W2000442546 @default.
• W2100032900 cites W2009891439 @default.
• W2100032900 cites W2013545125 @default.
• W2100032900 cites W2025479752 @default.
• W2100032900 cites W2030000278 @default.
• W2100032900 cites W2041868144 @default.
• W2100032900 cites W2047526581 @default.
• W2100032900 cites W2058117702 @default.
• W2100032900 cites W2066946030 @default.
• W2100032900 cites W2092704721 @default.
• W2100032900 cites W2111149452 @default.
• W2100032900 cites W2113698764 @default.
• W2100032900 cites W2114488753 @default.
• W2100032900 cites W2121087098 @default.
• W2100032900 cites W2129948097 @default.
• W2100032900 cites W2132498886 @default.
• W2100032900 cites W2135352158 @default.
• W2100032900 cites W2144030592 @default.
• W2100032900 cites W2146052740 @default.
• W2100032900 cites W2156806226 @default.
• W2100032900 cites W2157823046 @default.
• W2100032900 cites W2163206122 @default.
• W2100032900 cites W2170019085 @default.
• W2100032900 cites W2326799365 @default.
• W2100032900 cites W4241746836 @default.
• W2100032900 doi "https://doi.org/10.1016/s0149-2918(03)80125-x" @default.
• W2100032900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12867214" @default.
• W2100032900 hasPublicationYear "2003" @default.
• W2100032900 type Work @default.
• W2100032900 sameAs 2100032900 @default.
• W2100032900 citedByCount "164" @default.
• W2100032900 countsByYear W21000329002012 @default.
• W2100032900 countsByYear W21000329002013 @default.
• W2100032900 countsByYear W21000329002014 @default.
• W2100032900 countsByYear W21000329002015 @default.
• W2100032900 countsByYear W21000329002016 @default.
• W2100032900 countsByYear W21000329002017 @default.
• W2100032900 countsByYear W21000329002018 @default.
• W2100032900 countsByYear W21000329002019 @default.
• W2100032900 countsByYear W21000329002020 @default.
• W2100032900 countsByYear W21000329002021 @default.
• W2100032900 countsByYear W21000329002022 @default.
• W2100032900 countsByYear W21000329002023 @default.
• W2100032900 crossrefType "journal-article" @default.
• W2100032900 hasAuthorship W2100032900A5005031753 @default.
• W2100032900 hasAuthorship W2100032900A5006549736 @default.
• W2100032900 hasAuthorship W2100032900A5006700282 @default.
• W2100032900 hasAuthorship W2100032900A5017044459 @default.
• W2100032900 hasAuthorship W2100032900A5026816951 @default.
• W2100032900 hasAuthorship W2100032900A5041768647 @default.
• W2100032900 hasAuthorship W2100032900A5043753326 @default.
• W2100032900 hasAuthorship W2100032900A5049454568 @default.
• W2100032900 hasAuthorship W2100032900A5057230537 @default.
• W2100032900 hasAuthorship W2100032900A5058024552 @default.
• W2100032900 hasAuthorship W2100032900A5062472038 @default.
• W2100032900 hasAuthorship W2100032900A5086478412 @default.
• W2100032900 hasAuthorship W2100032900A5090864045 @default.
• W2100032900 hasConcept C126322002 @default.
• W2100032900 hasConcept C156957248 @default.
• W2100032900 hasConcept C16005928 @default.
• W2100032900 hasConcept C197934379 @default.
• W2100032900 hasConcept C2778375690 @default.
• W2100032900 hasConcept C2779548794 @default.
• W2100032900 hasConcept C2779629538 @default.
• W2100032900 hasConcept C2780306776 @default.
• W2100032900 hasConcept C71924100 @default.
• W2100032900 hasConcept C95190672 @default.
• W2100032900 hasConcept C98274493 @default.
• W2100032900 hasConceptScore W2100032900C126322002 @default.
• W2100032900 hasConceptScore W2100032900C156957248 @default.
• W2100032900 hasConceptScore W2100032900C16005928 @default.
• W2100032900 hasConceptScore W2100032900C197934379 @default.
• W2100032900 hasConceptScore W2100032900C2778375690 @default.
• W2100032900 hasConceptScore W2100032900C2779548794 @default.
• W2100032900 hasConceptScore W2100032900C2779629538 @default.

• next